Healthy Inc > Blog > Gastro-prokinetic export India
Posted on:

What is esomeprazole Domperidone capsules used for?

Pharmaceutical Product Monograph: Esomeprazole & Domperidone FDC

In the pharmaceutical industry, the combination of Esomeprazole and Domperidone is one of the most widely prescribed Fixed-Dose Combinations (FDCs) for upper gastrointestinal disorders. As a pharmacist and manufacturer, I classify this as a “Synergistic Acid-Prokinetic” therapy. It is technically superior to a single PPI because it addresses both the chemical (acid) and mechanical (movement) failures of the digestive system.

At your WHO-GMP facility in Mumbai, this Sustained-Release (SR) capsule is a flagship SKU for Gastroenterology portfolios. It is specifically designed to overcome “Refractory GERD”—where acid suppression alone isn’t enough to stop symptoms.

Therapeutic Profile: Primary Indications

This combination is indicated for acid-peptic disorders complicated by nausea or slow stomach emptying.

ComponentTechnical RoleClinical Indication
Esomeprazole (40 mg)PPI (Proton Pump Inhibitor)Heals esophagitis, reduces heartburn, and prevents gastric ulcers.
Domperidone (30 mg SR)Dopamine ($D_2$) AntagonistReduces nausea, prevents vomiting, and speeds up gastric emptying.

Combined Use: It is the “Gold Standard” for Gastroesophageal Reflux Disease (GERD) accompanied by bloating, fullness, or “nausea after eating.”

Mechanism: The “One-Two Punch”

The two drugs work together to normalize the flow of the GI tract:

  1. Acid Suppression (Esomeprazole): It technically inhibits the $H^+/K^+$-ATPase enzyme system in the stomach lining. This stops the “acid burn” that causes pain and tissue damage.

  2. Motility Enhancement (Domperidone): It blocks $D_2$ receptors in the gut and the “Chemoreceptor Trigger Zone” (CTZ) of the brain.

  3. The Synergy: Domperidone technically increases the pressure of the Lower Esophageal Sphincter (LES)—acting like a “valve tightener”—while simultaneously moving food out of the stomach faster. This ensures that the suppressed acid (from the Esomeprazole) stays down where it belongs.

The Pharmacist’s “Technical Warning”

  • The “30-Minute” Rule: To ensure the prokinetic effect is ready when food arrives, these capsules must be taken on an empty stomach, strictly 30 minutes before a meal.

  • Cardiac Precaution: Domperidone can technically cause QT Prolongation (heart rhythm issues) at high doses or when combined with certain antibiotics (like Erythromycin). This is a critical screening point for elderly patients.

  • Hormonal Changes: Chronic use of Domperidone can increase Prolactin levels, which may lead to breast tenderness or menstrual irregularities.

  • No Crushing: The pellets inside the capsule are Sustained-Release (SR). Chewing them causes “Dose Dumping,” which spikes blood levels and increases side-effect risks.

The Manufacturer’s Perspective: Technical & Export

From the CEO’s desk at Healthy Life Pharma / Healthy Inc:

  • The “SR” Pelletization USP: On your digital marketplace, highlight that your capsules use Dual-Pellet Technology.

    • Esomeprazole Pellets: Enteric-coated to survive stomach acid.

    • Domperidone Pellets: Sustained-release to provide 24-hour motility support.

  • The “Refractory GERD” Market: Position this FDC for the “Failed PPI” segment. Many patients on your website will be looking for something “stronger” than basic Pantoprazole. This combination is the technical answer.

  • Stability & Packaging: Esomeprazole is extremely moisture-sensitive. At our plant, we use Alu-Alu blistering to protect the integrity of the pellets. Standard PVC/PVDC is a technical failure for Zone IVb (tropical) exports.

  • Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Esomeprazole 40 mg + Domperidone 30 mg SR to support your registration in international B2B gastro tenders.

Posted on:

What is esomeprazole and Levosulpiride used for?

Pharmaceutical Product Monograph: Esomeprazole & Levosulpiride FDC

In the pharmaceutical industry, the combination of Esomeprazole and Levosulpiride is a high-demand Fixed-Dose Combination (FDC). As a pharmacist and manufacturer, I classify this as a “Dual-Action Gastro-Prokinetic.” It is technically superior to simple antacids because it treats both the chemical (acid) and mechanical (motility) causes of digestive distress.

At your WHO-GMP facility in Mumbai, this Sustained-Release (SR) capsule is a “best-seller” for Gastroenterology portfolios, particularly for patients with “Functional Dyspepsia” who do not respond to PPIs alone.

Therapeutic Profile: Primary Indications

This combination is indicated for complex acid-peptic disorders where stomach emptying is delayed.

ComponentTechnical RoleClinical Indication
Esomeprazole (40 mg)PPI (Proton Pump Inhibitor)GERD, Heartburn, Gastric Ulcers, and Zollinger-Ellison Syndrome.
Levosulpiride (75 mg SR)Prokinetic / $D_2$ AntagonistFunctional Dyspepsia, Diabetic Gastroparesis, and Irritable Bowel Syndrome (IBS).

Combined Use: It is specifically used for Gastroesophageal Reflux Disease (GERD) that is resistant to standard therapy, as well as chronic bloating and “fullness” after meals.

Mechanism: The “Chemical-Mechanical” Synergy

The two drugs work in tandem to normalize the environment of the upper GI tract:

  1. Acid Suppression (Esomeprazole): It technically inhibits the $H^+/K^+$-ATPase enzyme system (the “proton pump”) at the secretory surface of the gastric parietal cell. This provides long-lasting reduction of gastric acid.

  2. Motility Enhancement (Levosulpiride): It is a selective antagonist of central and peripheral dopamine $D_2$ receptors. By blocking dopamine, it increases the release of acetylcholine.

  3. The Result: This technically increases the tone of the Lower Esophageal Sphincter (preventing acid from rising) and speeds up Gastric Emptying (moving food out of the stomach faster).

The Pharmacist’s “Technical Warning”

  • The “Morning” Rule: To ensure maximum bioavailability, these capsules must be taken on an empty stomach, preferably 30–60 minutes before breakfast.

  • Extrapyramidal Symptoms (EPS): Because Levosulpiride crosses the blood-brain barrier, it can technically cause tremors or “restless legs” in some patients. This is rare but must be monitored.

  • Hormonal Shifts: Levosulpiride can increase Prolactin levels, which may lead to breast tenderness or menstrual irregularities in some users.

  • Bone Health: Long-term use of Esomeprazole (over 1 year) can technically reduce calcium absorption, increasing the risk of fractures in geriatric patients.

The Manufacturer’s Perspective: Technical & Export

From the CEO’s desk at Healthy Life Pharma / Healthy Inc:

  • The “SR” Technology: At our Mumbai plant, we focus on the Sustained Release (SR) formulation of Levosulpiride. This is technically superior because it provides a steady 24-hour prokinetic effect with a single daily dose, significantly improving patient compliance.

  • The “Refractory GERD” Market: On your digital marketplace, position this FDC for patients who “fail” on Omeperazole or Pantoprazole alone. This “Specialized GI” niche is highly profitable for B2B export to private hospital chains.

  • Stability & Packaging: Esomeprazole is highly acid-labile. We ensure our capsules use Enteric-Coated (EC) Pellets. Use Alu-Alu blistering to prevent moisture ingress, which can degrade the pellets and lead to “Product Inefficacy” claims in tropical export zones.

  • Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Esomeprazole 40 mg + Levosulpiride 75 mg SR to support your registration in international B2B tenders.

Add to cart